Logo

Eli Lilly and Boehringer Ingelheim Report Cardiovascular Outcomes of Tradjenta (linagliptin) in CAROLINA Study for Type 2 Diabetes

Share this

Eli Lilly and Boehringer Ingelheim Report Cardiovascular Outcomes of Tradjenta (linagliptin) in CAROLINA Study for Type 2 Diabetes

Shots:

  • (NCT01243424) study results involve assessing of Tradjenta (5mg- qd) vs glimepiride in patients with type2 diabetes across 43 countries for 6+years
  • The CAROLINA study resulted in meeting its 1EPs i.e- occurrence of 3P-MACE (11.8% vs 12.0%)- 3P-MACE + 4P-MACE (13.2% vs 13.3%)- 2EPs (16.0% vs 10.2%)- 77% reduction in risk of hypoglycemia; no new safety signals is observed
  • Tradjenta is dipeptidyl peptidase-4 (DPP-4) inhibitor indicated with diet and exercise to reduce blood sugar in adults with type 2 diabetes

Ref: Eli Lilly | Image: Eli Lilly

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions